Trial
NCT04793399
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Collaborators
Pfizer; Roche Farma, S.A
Condition
Chronic Phase-Chronic Myeloid Leukemia
Intervention
Bosutinib 400 MG Monotherapy
Why stopped
The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-19